Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial
Background A prospective randomized trial was conducted to compare the impact of systemic chemotherapy versus multi‐modality therapy (complete cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and systemic chemotherapy) on overall survival (OS) in patients with gastric...
Gespeichert in:
| Veröffentlicht in: | Journal of surgical oncology 2014-09, Vol.110 (3), p.275-284 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 284 |
|---|---|
| container_issue | 3 |
| container_start_page | 275 |
| container_title | Journal of surgical oncology |
| container_volume | 110 |
| creator | Rudloff, Udo Langan, Russell C. Mullinax, John E. Beane, Joal D. Steinberg, Seth M. Beresnev, Tatiana Webb, Carole C. Walker, Melissa Toomey, Mary Ann Schrump, David Pandalai, Prakash Stojadinovic, Alexander Avital, Itzhak |
| description | Background
A prospective randomized trial was conducted to compare the impact of systemic chemotherapy versus multi‐modality therapy (complete cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and systemic chemotherapy) on overall survival (OS) in patients with gastric carcinomatosis.
Methods
Patients with measurable metastatic gastric adenocarcinoma involving the peritoneum, and resectable to “no evidence of disease” were randomized to gastrectomy, metastasectomy, HIPEC, and systemic FOLFOXIRI (GYMS arm) or FOLFOXIRI alone (SA arm).
Results
Seventeen patients were enrolled (16 evaluable); 7 of 9 patients in the multi‐modality GYMS arm achieved complete cytoreduction (CCR0). Median OS was 11.3 months in the GYMS arm and 4.3 months in the SA arm. Four patients in the GYMS arm survived >12 months, 2 patients close to 2 years at last follow‐up, and 1 patient more than 4 years, with 2 of these patients still alive. No patient in the SA arm lived beyond 11 months. All patients surviving beyond 12 months in the surgery arm achieved complete cytoreduction and had an initial Peritoneal Cancer Index (PCI) of ≤15.
Conclusion
Maximal cytoreductive surgery combined with regional (HIPEC) and systemic chemotherapy in selected patients with gastric carcinomatosis and limited disease burden can achieve prolonged survival. J. Surg. Oncol. 2014 110:275–284. © 2014 Wiley Periodicals, Inc. |
| doi_str_mv | 10.1002/jso.23633 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1553148988</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3402361711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4513-8e397f9c4c4b4bc34d6af2cbbac602d399c21567748f3473a22876a42253e0673</originalsourceid><addsrcrecordid>eNp1kc9u1DAQxiMEotvCgRdAlri0h7SO7fwxt2pVdrfqtogFASfLcSa7XpI42E7bvCDPhbfbVlw4jTTz-77RzBdF7xJ8mmBMzrbOnBKaUfoimiSYZzHHvHgZTcKMxCzn-CA6dG6LMeY8Y6-jA5JiRnKMJ9GfRdtL5ZGpUSvvdSsbpEZvLFSD8voWkBvsGuyI-mZwyMJamy4wG5AeKqQ7b2UPVnvTwU66gdb4DYTmiI7ni88X0xNkOmQGr0wLuy299Bo679Cd9hv0r1ZapTvTSm-cdjt0LZ23WiFj9Vp3H9EXcEPjH0ZhB5r9XK5W5yggsnkTvapl4-DtYz2Kvn26-Dqdx1c3s8X0_CpWLE1oXADlec0VU6xkpaKsymRNVFlKlWFSUc4VSdIsz1lRU5ZTSUiRZ5IRklLAWU6Pog97396a3wM4L7ZmsOEjTiRpShNW8KII1MmeUtY4Z6EWvQ2vtaNIsNglJkJi4iGxwL5_dBzKFqpn8imiAJztgTvdwPh_J3G5unmyjPcK7TzcPyuk_SXCCXkqvl_PxPJy-mNeXC9FSv8Cow2y1w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1553148988</pqid></control><display><type>article</type><title>Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Rudloff, Udo ; Langan, Russell C. ; Mullinax, John E. ; Beane, Joal D. ; Steinberg, Seth M. ; Beresnev, Tatiana ; Webb, Carole C. ; Walker, Melissa ; Toomey, Mary Ann ; Schrump, David ; Pandalai, Prakash ; Stojadinovic, Alexander ; Avital, Itzhak</creator><creatorcontrib>Rudloff, Udo ; Langan, Russell C. ; Mullinax, John E. ; Beane, Joal D. ; Steinberg, Seth M. ; Beresnev, Tatiana ; Webb, Carole C. ; Walker, Melissa ; Toomey, Mary Ann ; Schrump, David ; Pandalai, Prakash ; Stojadinovic, Alexander ; Avital, Itzhak</creatorcontrib><description>Background
A prospective randomized trial was conducted to compare the impact of systemic chemotherapy versus multi‐modality therapy (complete cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and systemic chemotherapy) on overall survival (OS) in patients with gastric carcinomatosis.
Methods
Patients with measurable metastatic gastric adenocarcinoma involving the peritoneum, and resectable to “no evidence of disease” were randomized to gastrectomy, metastasectomy, HIPEC, and systemic FOLFOXIRI (GYMS arm) or FOLFOXIRI alone (SA arm).
Results
Seventeen patients were enrolled (16 evaluable); 7 of 9 patients in the multi‐modality GYMS arm achieved complete cytoreduction (CCR0). Median OS was 11.3 months in the GYMS arm and 4.3 months in the SA arm. Four patients in the GYMS arm survived >12 months, 2 patients close to 2 years at last follow‐up, and 1 patient more than 4 years, with 2 of these patients still alive. No patient in the SA arm lived beyond 11 months. All patients surviving beyond 12 months in the surgery arm achieved complete cytoreduction and had an initial Peritoneal Cancer Index (PCI) of ≤15.
Conclusion
Maximal cytoreductive surgery combined with regional (HIPEC) and systemic chemotherapy in selected patients with gastric carcinomatosis and limited disease burden can achieve prolonged survival. J. Surg. Oncol. 2014 110:275–284. © 2014 Wiley Periodicals, Inc.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.23633</identifier><identifier>PMID: 25042700</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - secondary ; Adenocarcinoma - therapy ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Camptothecin - analogs & derivatives ; Camptothecin - therapeutic use ; Chemotherapy ; Chemotherapy, Cancer, Regional Perfusion ; cytoreductive surgery ; Female ; Fluorouracil - therapeutic use ; Gastrectomy ; heated intraperitoneal chemotherapy (HIPEC) ; Humans ; Hyperthermia, Induced ; Kaplan-Meier Estimate ; Leucovorin - therapeutic use ; Liver Neoplasms - mortality ; Liver Neoplasms - secondary ; Liver Neoplasms - therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - secondary ; Lung Neoplasms - therapy ; Male ; metastasectomy ; metastatic gastric cancer ; Middle Aged ; Organoplatinum Compounds - therapeutic use ; Ovarian cancer ; Patients ; Peritoneal Neoplasms - mortality ; Peritoneal Neoplasms - secondary ; Peritoneal Neoplasms - therapy ; Peritoneum - surgery ; Prospective Studies ; Stomach Neoplasms - mortality ; Stomach Neoplasms - pathology ; Stomach Neoplasms - therapy ; Surgery</subject><ispartof>Journal of surgical oncology, 2014-09, Vol.110 (3), p.275-284</ispartof><rights>2014 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4513-8e397f9c4c4b4bc34d6af2cbbac602d399c21567748f3473a22876a42253e0673</citedby><cites>FETCH-LOGICAL-c4513-8e397f9c4c4b4bc34d6af2cbbac602d399c21567748f3473a22876a42253e0673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.23633$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.23633$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25042700$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rudloff, Udo</creatorcontrib><creatorcontrib>Langan, Russell C.</creatorcontrib><creatorcontrib>Mullinax, John E.</creatorcontrib><creatorcontrib>Beane, Joal D.</creatorcontrib><creatorcontrib>Steinberg, Seth M.</creatorcontrib><creatorcontrib>Beresnev, Tatiana</creatorcontrib><creatorcontrib>Webb, Carole C.</creatorcontrib><creatorcontrib>Walker, Melissa</creatorcontrib><creatorcontrib>Toomey, Mary Ann</creatorcontrib><creatorcontrib>Schrump, David</creatorcontrib><creatorcontrib>Pandalai, Prakash</creatorcontrib><creatorcontrib>Stojadinovic, Alexander</creatorcontrib><creatorcontrib>Avital, Itzhak</creatorcontrib><title>Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial</title><title>Journal of surgical oncology</title><addtitle>J. Surg. Oncol</addtitle><description>Background
A prospective randomized trial was conducted to compare the impact of systemic chemotherapy versus multi‐modality therapy (complete cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and systemic chemotherapy) on overall survival (OS) in patients with gastric carcinomatosis.
Methods
Patients with measurable metastatic gastric adenocarcinoma involving the peritoneum, and resectable to “no evidence of disease” were randomized to gastrectomy, metastasectomy, HIPEC, and systemic FOLFOXIRI (GYMS arm) or FOLFOXIRI alone (SA arm).
Results
Seventeen patients were enrolled (16 evaluable); 7 of 9 patients in the multi‐modality GYMS arm achieved complete cytoreduction (CCR0). Median OS was 11.3 months in the GYMS arm and 4.3 months in the SA arm. Four patients in the GYMS arm survived >12 months, 2 patients close to 2 years at last follow‐up, and 1 patient more than 4 years, with 2 of these patients still alive. No patient in the SA arm lived beyond 11 months. All patients surviving beyond 12 months in the surgery arm achieved complete cytoreduction and had an initial Peritoneal Cancer Index (PCI) of ≤15.
Conclusion
Maximal cytoreductive surgery combined with regional (HIPEC) and systemic chemotherapy in selected patients with gastric carcinomatosis and limited disease burden can achieve prolonged survival. J. Surg. Oncol. 2014 110:275–284. © 2014 Wiley Periodicals, Inc.</description><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - secondary</subject><subject>Adenocarcinoma - therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Camptothecin - therapeutic use</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Cancer, Regional Perfusion</subject><subject>cytoreductive surgery</subject><subject>Female</subject><subject>Fluorouracil - therapeutic use</subject><subject>Gastrectomy</subject><subject>heated intraperitoneal chemotherapy (HIPEC)</subject><subject>Humans</subject><subject>Hyperthermia, Induced</subject><subject>Kaplan-Meier Estimate</subject><subject>Leucovorin - therapeutic use</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - secondary</subject><subject>Liver Neoplasms - therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - secondary</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>metastasectomy</subject><subject>metastatic gastric cancer</subject><subject>Middle Aged</subject><subject>Organoplatinum Compounds - therapeutic use</subject><subject>Ovarian cancer</subject><subject>Patients</subject><subject>Peritoneal Neoplasms - mortality</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Peritoneal Neoplasms - therapy</subject><subject>Peritoneum - surgery</subject><subject>Prospective Studies</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - pathology</subject><subject>Stomach Neoplasms - therapy</subject><subject>Surgery</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9u1DAQxiMEotvCgRdAlri0h7SO7fwxt2pVdrfqtogFASfLcSa7XpI42E7bvCDPhbfbVlw4jTTz-77RzBdF7xJ8mmBMzrbOnBKaUfoimiSYZzHHvHgZTcKMxCzn-CA6dG6LMeY8Y6-jA5JiRnKMJ9GfRdtL5ZGpUSvvdSsbpEZvLFSD8voWkBvsGuyI-mZwyMJamy4wG5AeKqQ7b2UPVnvTwU66gdb4DYTmiI7ni88X0xNkOmQGr0wLuy299Bo679Cd9hv0r1ZapTvTSm-cdjt0LZ23WiFj9Vp3H9EXcEPjH0ZhB5r9XK5W5yggsnkTvapl4-DtYz2Kvn26-Dqdx1c3s8X0_CpWLE1oXADlec0VU6xkpaKsymRNVFlKlWFSUc4VSdIsz1lRU5ZTSUiRZ5IRklLAWU6Pog97396a3wM4L7ZmsOEjTiRpShNW8KII1MmeUtY4Z6EWvQ2vtaNIsNglJkJi4iGxwL5_dBzKFqpn8imiAJztgTvdwPh_J3G5unmyjPcK7TzcPyuk_SXCCXkqvl_PxPJy-mNeXC9FSv8Cow2y1w</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Rudloff, Udo</creator><creator>Langan, Russell C.</creator><creator>Mullinax, John E.</creator><creator>Beane, Joal D.</creator><creator>Steinberg, Seth M.</creator><creator>Beresnev, Tatiana</creator><creator>Webb, Carole C.</creator><creator>Walker, Melissa</creator><creator>Toomey, Mary Ann</creator><creator>Schrump, David</creator><creator>Pandalai, Prakash</creator><creator>Stojadinovic, Alexander</creator><creator>Avital, Itzhak</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope></search><sort><creationdate>20140901</creationdate><title>Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial</title><author>Rudloff, Udo ; Langan, Russell C. ; Mullinax, John E. ; Beane, Joal D. ; Steinberg, Seth M. ; Beresnev, Tatiana ; Webb, Carole C. ; Walker, Melissa ; Toomey, Mary Ann ; Schrump, David ; Pandalai, Prakash ; Stojadinovic, Alexander ; Avital, Itzhak</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4513-8e397f9c4c4b4bc34d6af2cbbac602d399c21567748f3473a22876a42253e0673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - secondary</topic><topic>Adenocarcinoma - therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Camptothecin - therapeutic use</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Cancer, Regional Perfusion</topic><topic>cytoreductive surgery</topic><topic>Female</topic><topic>Fluorouracil - therapeutic use</topic><topic>Gastrectomy</topic><topic>heated intraperitoneal chemotherapy (HIPEC)</topic><topic>Humans</topic><topic>Hyperthermia, Induced</topic><topic>Kaplan-Meier Estimate</topic><topic>Leucovorin - therapeutic use</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - secondary</topic><topic>Liver Neoplasms - therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - secondary</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>metastasectomy</topic><topic>metastatic gastric cancer</topic><topic>Middle Aged</topic><topic>Organoplatinum Compounds - therapeutic use</topic><topic>Ovarian cancer</topic><topic>Patients</topic><topic>Peritoneal Neoplasms - mortality</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Peritoneal Neoplasms - therapy</topic><topic>Peritoneum - surgery</topic><topic>Prospective Studies</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - pathology</topic><topic>Stomach Neoplasms - therapy</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rudloff, Udo</creatorcontrib><creatorcontrib>Langan, Russell C.</creatorcontrib><creatorcontrib>Mullinax, John E.</creatorcontrib><creatorcontrib>Beane, Joal D.</creatorcontrib><creatorcontrib>Steinberg, Seth M.</creatorcontrib><creatorcontrib>Beresnev, Tatiana</creatorcontrib><creatorcontrib>Webb, Carole C.</creatorcontrib><creatorcontrib>Walker, Melissa</creatorcontrib><creatorcontrib>Toomey, Mary Ann</creatorcontrib><creatorcontrib>Schrump, David</creatorcontrib><creatorcontrib>Pandalai, Prakash</creatorcontrib><creatorcontrib>Stojadinovic, Alexander</creatorcontrib><creatorcontrib>Avital, Itzhak</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rudloff, Udo</au><au>Langan, Russell C.</au><au>Mullinax, John E.</au><au>Beane, Joal D.</au><au>Steinberg, Seth M.</au><au>Beresnev, Tatiana</au><au>Webb, Carole C.</au><au>Walker, Melissa</au><au>Toomey, Mary Ann</au><au>Schrump, David</au><au>Pandalai, Prakash</au><au>Stojadinovic, Alexander</au><au>Avital, Itzhak</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J. Surg. Oncol</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>110</volume><issue>3</issue><spage>275</spage><epage>284</epage><pages>275-284</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Background
A prospective randomized trial was conducted to compare the impact of systemic chemotherapy versus multi‐modality therapy (complete cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and systemic chemotherapy) on overall survival (OS) in patients with gastric carcinomatosis.
Methods
Patients with measurable metastatic gastric adenocarcinoma involving the peritoneum, and resectable to “no evidence of disease” were randomized to gastrectomy, metastasectomy, HIPEC, and systemic FOLFOXIRI (GYMS arm) or FOLFOXIRI alone (SA arm).
Results
Seventeen patients were enrolled (16 evaluable); 7 of 9 patients in the multi‐modality GYMS arm achieved complete cytoreduction (CCR0). Median OS was 11.3 months in the GYMS arm and 4.3 months in the SA arm. Four patients in the GYMS arm survived >12 months, 2 patients close to 2 years at last follow‐up, and 1 patient more than 4 years, with 2 of these patients still alive. No patient in the SA arm lived beyond 11 months. All patients surviving beyond 12 months in the surgery arm achieved complete cytoreduction and had an initial Peritoneal Cancer Index (PCI) of ≤15.
Conclusion
Maximal cytoreductive surgery combined with regional (HIPEC) and systemic chemotherapy in selected patients with gastric carcinomatosis and limited disease burden can achieve prolonged survival. J. Surg. Oncol. 2014 110:275–284. © 2014 Wiley Periodicals, Inc.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25042700</pmid><doi>10.1002/jso.23633</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2014-09, Vol.110 (3), p.275-284 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_proquest_journals_1553148988 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - secondary Adenocarcinoma - therapy Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Camptothecin - analogs & derivatives Camptothecin - therapeutic use Chemotherapy Chemotherapy, Cancer, Regional Perfusion cytoreductive surgery Female Fluorouracil - therapeutic use Gastrectomy heated intraperitoneal chemotherapy (HIPEC) Humans Hyperthermia, Induced Kaplan-Meier Estimate Leucovorin - therapeutic use Liver Neoplasms - mortality Liver Neoplasms - secondary Liver Neoplasms - therapy Lung Neoplasms - mortality Lung Neoplasms - secondary Lung Neoplasms - therapy Male metastasectomy metastatic gastric cancer Middle Aged Organoplatinum Compounds - therapeutic use Ovarian cancer Patients Peritoneal Neoplasms - mortality Peritoneal Neoplasms - secondary Peritoneal Neoplasms - therapy Peritoneum - surgery Prospective Studies Stomach Neoplasms - mortality Stomach Neoplasms - pathology Stomach Neoplasms - therapy Surgery |
| title | Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A42%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20maximal%20cytoreductive%20surgery%20plus%20regional%20heated%20intraperitoneal%20chemotherapy%20(HIPEC)%20on%20outcome%20of%20patients%20with%20peritoneal%20carcinomatosis%20of%20gastric%20origin:%20Results%20of%20the%20GYMSSA%20trial&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Rudloff,%20Udo&rft.date=2014-09-01&rft.volume=110&rft.issue=3&rft.spage=275&rft.epage=284&rft.pages=275-284&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.23633&rft_dat=%3Cproquest_cross%3E3402361711%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1553148988&rft_id=info:pmid/25042700&rfr_iscdi=true |